News | Radiopharmaceuticals and Tracers | October 12, 2018

CORAR Supports Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018

Federal legislation would institute separate payment policy for diagnostic radiopharmaceuticals under the Medicare Hospital Outpatient Prospective Payment System (OPPS)

CORAR Supports Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018

October 12, 2018 — The Council on Radionuclides and Radiopharmaceuticals Inc. (CORAR) — the voice of the radionuclide, radiopharmaceutical and nuclear pharmacy industries in North America — strongly supports legislation recently introduced by Congressman George Holding (R-NC-2) and Seth Moulton (D-MA-6). This legislation, designated H.R. 6948 - Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018, would direct the Secretary of Health and Human Services to recognize diagnostic radiopharmaceuticals (RPs) as drugs and institute a separate payment policy under the Medicare Hospital Outpatient Prospective Payment System (OPPS).

According to the Society of Nuclear Medicine and Molecular Imaging (SNMMI), more than 20 million Americans benefit each year from nuclear medicine procedures.1 Diagnostic RPs are drugs necessary for all nuclear medicine imaging studies to diagnose and determine the severity of disease. Nuclear medicine imaging procedures are effectively used in the diagnosis and treatment of disease states such as cardiovascular disease, some forms of cancer, Parkinson’s Disease, thyroid disease and epilepsy.

Diagnostic and therapeutic RPs are statutorily considered drugs and are regulated as drugs by the Food and Drug Administration. However, since 2009 diagnostic RPs under the OPPS have been packaged with the procedure into Ambulatory Payment Classifications (APCs) for a bundled payment to hospitals while therapeutic RPs continue to be paid separately. Diagnostic RP costs may vary widely within a nuclear medicine APC with some diagnostic RP costs significantly exceeding the APC payment rate.

The Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018 will ensure that diagnostic RPs are recognized as drugs and that all diagnostic RPs are appropriately paid under the OPPS. This will safeguard patient access to newer precision diagnostic RPs and support more innovation to improve clinical outcomes and deliver more cost-effective care, according to CORAR.

For more information: www.corar.org

Reference

  1. Society of Nuclear Medicine and Molecular Imaging, http://www.snmmi.org/ClinicalPractice/content.aspx?ItemNumber=4825

Related Content

Feature | Nuclear Imaging | By Staff of the American Society of Nuclear Cardiology (ASNC)

A year after COVID-19 turned the world upside down, the American Society of Nuclear Cardiology (ASNC) asked members how ...

Home June 02, 2021
Home
News | Nuclear Imaging

April 1, 2021 – The ability to measure myocardial blood flow (MBF) as part of myocardial perfusion imaging (MPI) is one ...

Home April 01, 2021
Home
News | Nuclear Imaging

December 4, 2020 — Spectrum Dynamics Medical, Inc., has received Canadian Medical Device License from Health Canada for ...

Home December 04, 2020
Home
News | Nuclear Imaging

September 30, 2020 — Siemens Healthineers has introduced a new version of its c.cam dedicated cardiac nuclear medicine ...

Home October 07, 2020
Home
Feature | Nuclear Imaging | Dave Fornell, Editor

There were a few key takeaways from the American Society of Nuclear Cardiology (ASNC) 2019 annual meeting in September ...

Home November 22, 2019
Home
Videos | Nuclear Imaging

Rob Beanlands, M.D., FASNC, 2019 American Society of Nuclear Cardiology (ASNC) president, shares a couple trends he sees ...

Home November 07, 2019
Home
Videos | Nuclear Imaging

Robert C. Hendel, M.D., explains some of the new cardiac radiotracers in the pipeline that were discussed in sessions at ...

Home November 06, 2019
Home
Feature | Nuclear Imaging | Christopher A. Hanson M.D., and Jamieson M. Bourque M.D., MHS

Cardiac amyloidosis is a highly morbid and underdiagnosed infiltrative cardiomyopathy that is characterized by the ...

Home July 22, 2019
Home
Videos | Nuclear Imaging

Raza Alvi, M.D., a research fellow in radiology at Massachusetts General Hospital, has been involved in a study of a ...

Home March 22, 2019
Home
News | Nuclear Imaging

November 15, 2018 — GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident ...

Home November 15, 2018
Home
Subscribe Now